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Abstract  
BACKGROUND: Leishmaniasis is a parasitic disease affecting both animals and humans, acquired with the bite 
of sand flies or, in Injection Drug Users (IDUs), with contaminated needles, still hypoendemic in Sicily and the 
Mediterranean basin. Even though it is responsible for 20,000 to 40,000 deaths per year, this parasitic infection is 
still considered a neglected tropical disease. People Living with HIV (PLWH) are considered at high-risk of 
developing Leishmaniasis and, despite the introduction of Highly Active Anti-Retroviral Therapy (HAART), 
mortality rate and relapses prevalence are still high in coinfected people. 
CASE REPORT: We present a case of HIV-Leishmania coinfection, posing the attention on the atypical signs and 
symptoms and the importance of thinking about other causes than the HIV infection progression when the patient 
presents with a worsening of his immune status during HAART. 
CONCLUSION: This parasitic disease has a high mortality rate, so it is mandatory to think about it in all the 
patients having a low CD4+ T-cell count and an inverted CD4/CD8 ratio under HAART. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
After the introduction of Highly Active Anti-
Retroviral Therapy (HAART) mean age and 
comorbidities related to ageing, immune suppression, 
coinfections and persistent inflammation increased in 
People Living with HIV (PLWH) [1] [2] [3] [4] [5] [6] [7] 
[8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 
[21] [22] [23] [24] [25] [26] [27]. 
Among the coinfections commonly observed 
in PLWH, there is Leishmaniasis, which is still 
considered a neglected tropical disease, affecting 
immunocompromised people, and especially PLWH, 
more than the immunocompetent population, being 
responsible for 20,000 to 40,000 deaths per year [28]. 
PLWH are considered at high-risk of 
developing Leishmaniasis because of the two 
infections geographical distribution: areas, where the 
HIV infection have a high prevalence, are usually also 
areas where the Leishmania infection is widespread 
[29]. 
Despite the introduction of HAART 
significantly reduced the coinfection prevalence, 
mortality rate and relapses prevalence are still high in 
immunocompromised people [29][31]. Prognosis is 
also affected by the nutritional status of the patient 
[29]. 
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Treatment is difficult in immunocompromised 
people, because of the role of both constitutive 
immunodepression and Leishmania-related 
immunodepression on the response to the infection 
[28] [31] [32] [33] [34]. 
Here we present a case of HIV-Leishmania 
coinfection during which the patient developed some 
atypical signs before the appearance of a more typical 
Leishmaniasis clinical presentation allowed the 
diagnosis. 
 
 
Case Report 
 
A 52-years-old HIV-positive man, followed in 
our outpatient clinic since 1999 for his infection, came 
to the Emergency Ward of our University Hospital in 
August 2017, complaining of diarrhoea (defined as 
defecation of yellow liquid faeces at least five times 
per day) for two months. He lived in a poor health 
condition setting, and he was a smoker. He always 
lived in Sicily and never left the island. 
Until November 2015 he was on combined 
anti-retroviral therapy (cART) with 
emtricitabine/tenofovir disoproxil (FTC/TDF) and 
raltegravir (RAL), with successful virologic (HIV-RNA 
not detectable) and partially successful immunological 
(CD4+ 491/μl, 24%) control, but he was lost to follow-
up for a year. In January 2017 he was admitted to the 
Thoracic Surgery Unit of our hospital for a massive left 
pleural effusion, drained through a chest tube. An 
incomplete immunological control was highlighted 
(CD4+ T-cells 62/ μl, 7%; CD8+ T-cells 630/ μl, 71%, 
CD4/CD8 0.09) at that time. Therefore, he started a 
cART with darunavir/cobicistat (DRV/COBI) and RAL, 
with a successful virologic control (HIV-RNA not 
detectable), and a slight improvement of his 
immunological control (CD4+ 82/μl, 11 %) at the last 
blood testing, which took place in May. 
At the admission, he complained of asthenia. 
He reported that he had autonomously suspended 
cART, thinking that the diarrhoea was an adverse 
effect of the therapy, with no improvement. The 
physical examination revealed extreme dehydration 
and moderate hepatosplenomegaly. Moreover, a 
hyperemic hyperthermic painful lesion was highlighted 
on his left side, around the area where the chest tube 
was positioned in January. He was feverish (37.5 °C), 
while blood pressure and heart rate were normal. 
Blood tests showed anemia (Hb 9.9 g/dl), leukopenia 
(WBC 3,260/μl) and thrombocytopenia (PLTS 
109,000/μl); hypoalbuminemia (1.7 g/dl); monoclonal 
hypergammaglobulinemia (65.58%, normal 10.5 - 
19.5%). He began an intravenous (IV) therapy with 
albumin and IV hydration, and a cART with DRV/COBI 
and RAL was started again. 
During the admission his conditions 
worsened, making it necessary to perform a blood 
transfusion on August, 5
th
. Table 1 resumes altered 
results of the blood tests performed on our patient 
during the admission.  
Table 1: Blood test results during the admission 
 
Aug, 2
nd
 Aug, 4
th
 Aug, 5
th
 Aug, 6
th
 Aug, 8
th
 
Aug, 
11
th
 
Aug, 
16
th
 
WBC/ μl 3.280 1.990 2.170 2.080 2.460 1.860 2.140 
N (%) 55 56 52 56 50 61 54 
N/ μl 1.810 1.114 1.128 1.165 1.230 1.135 1.156 
L (%) 38 37 43 37 44 33 40 
L/ μl 1.250 736 933 770 1.082 614 856 
CD3 (%) 
 
87 
     
CD3/ μl 
 
641 
     
CD4 (%) 
 
8 
     
CD4/μl 
 
59 
     
CD8 (%) 
 
71 
     
CD8/ μl 
 
523 
     
CD4/CD8 
 
0,11 
     
CD19 (%) 
 
7 
     
CD19/ μl 
 
52 
     
CD20 (%) 
 
5 
     
CD20/ μl 
 
37 
     
CD34 gated (%) 
 
0,02 
     
CD34 vital/ μl 
 
1,96 
     
PLTS 109,000 91,000 71,000 74,000 87,000 103,000 138,000 
Hb (g/dl) 9,9 8,2 7,6 8,4 9,7 8,7 8,6 
CRP (mg/dl) 12,80 
 
6,30 
 
6,70 6,30 1,50 
PCT (ng/ml) 
 
0,44 
    
0,3 
Albumin (g/dl) 1,7 
   
2,02 2,34 2,8 
γ-globulin (%) 65,58 
   
61,4 58,66 
 
 
As it can be seen, his immunological control 
had worsened, revealing a CD4+ T-cell count of 59/μl 
(8%), with a CD8+ T-cell count of 523/μl (71%) and a 
resulting CD4+/CD8+ ratio of 0.11. 
Stool examinations (research of the 
Clostridium difficile toxin, parasitic infections and stool 
cultures, faecal occult blood) were performed, 
resulting in negative. Suspecting multiple myeloma, 
the patient underwent a bone marrow biopsy to 
determine the cause of the pancytopenia. No biopsy 
was performed on the flank skin lesion. 
Indirect immunofluorescence assay (IFAT) 
and Polymerase Chain Reaction (PCR) for the 
research of a Leishmania infection were performed on 
the 4
th
 day after the admission, resulting in positive 
(PCR 11,500 Leishmania/ml; IFAT 1:5120) on the 8
th
 
day after the admission. 
He then began a treatment with Liposomal 
Amphotericin B (L-AMB) 4 mg/kg/day on days 1 to 5, 
according to the Italian guidelines for the diagnosis 
and management of HIV infection (2016 edition) of the 
Italian Society of Infectious and Tropical Diseases 
(ISITD), and he repeated the treatment on days 10, 
17, 24, 31 and 38, completing the cycle [35]. He was 
discharged on the 14
th
 day after the admission and 
completed the treatment as an outpatient. Diarrhoea 
and the hyperemic lesion on his flank completely 
disappeared after the fifth day of therapy with L-AMB. 
Figure 1 shows the Serum Protein Electrophoresis (S-
PEP) trend before, during and at the end of the 
therapy. Secondary prophylaxis was not started, and 
the patient is still in follow up for the possibility of VL 
relapses. 
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Figure 1: S-PEP before (A); during (B) and after completing (C) the 
therapy with L-AMB 
 
 
 
Discussion 
 
Leishmaniasis is a parasitic disease affecting 
both animals and humans, acquired with the bite of 
sand flies or, in Injection Drug Users (IDUs), with 
contaminated needles, still hypoendemic in Sicily and 
the Mediterranean basin [34] [36].  
It is a known opportunistic disease in People 
Living with HIV (PLWH), whose immunodeficiency 
promotes visceral localisation, even though the 
coinfection prevalence reduced after the introduction 
of HAART [33] [36] [37]. Moreover, Leishmania spp 
can promote viral replication and enhance progression 
to Acquired Immuno-Deficiency Syndrome (AIDS) 
[34]. As a result, despite the introduction of HAART, 
relapses are still common, and mortality is three times 
higher in HIV-Leishmania coinfection than in HIV-
negative people affected by Leishmania infection [30] 
[31].  
Cota and al [33] reported in 2017 that CD4 T-
cell count at the moment of the diagnosis is not able 
to foresee the patient’s prognosis. However, 
resolution of the infection depends on an efficient 
CD4+ T-cell response, and it was observed that a 
higher incidence of symptoms is related to a lower 
CD4+ T-cell count [31] [32].  
The most frequent signs and symptoms of this 
infection are fever, asthenia, weight loss and 
splenomegaly; unspecific symptoms that could often 
lead to a delay in the diagnosis [31] [34]. Also, PLWH 
can complain of misleading non-classical symptoms 
[29]. 
In our case, the patient came to our attention 
in January, after more than a year of likely therapeutic 
vacation, with a seriously impaired immunological 
control. At the time he did not have any classical sign 
of the infection (normal S-PEP, no signs of 
pancytopenia, no hepatosplenomegaly), but it has 
been reported that Leishmaniasis can be related to 
pleural effusion, especially in PLWH with a very low 
CD4+ T-cell count [38]. Moreover, Infectious Diseases 
Society of America (IDSA) 2016 guidelines report that 
in PLWH the number of asymptomatic carriers of 
Leishmania seems to be higher than in the 
immunocompetent host [39]. Therefore, it can be 
supposed that our patient’s disease began some time 
before the classical signs appeared.  
An active response to Leishmania, leading to 
the infection control, is associated to host adaptive 
immunity, but, at the same time, to natural immunity 
[40]. The most influential factor in the immune 
response in Leishmaniasis seems to be the early 
interaction of the parasite with macrophages and 
dendritic cells [41]. 
Moreover, it has been observed an enhanced 
secretion of Th2 cytokines, and in particular IL-10, in 
Visceral Leishmaniasis associated to HIV-infection, 
which can promote the dissemination of both the virus 
and the parasite [28] [32] [40] [41] [42] [43]. 
Our patient presented to our attention, both in 
January and August, with a profoundly impaired 
immunological control, defined as a very low CD4+ T-
cell count and an inverted CD4/CD8 ratio, despite 
having a suppressed VL, a common sign during 
visceral Leishmaniasis [42]. However, the fact the 
patient came from a period of therapeutic vacation 
made difficult to think to other causes of severe 
immunodepression than his HIV infection, leading to 
the possibility of a diagnostic delay. 
The CD4/CD8 ratio is a marker of immune 
dysfunction leading to persistent inflammation in 
PLWH, and a low ratio can predict an impaired CD4+ 
T-cell count recovery before the start of the HAART 
[44]. During visceral leishmaniasis, CD8+ T-cells, and 
especially those expressing CD38, or activated CD8+ 
T-cells, increase, leading to a status of chronic 
inflammation which results in a T cell depletion, 
establishing a vicious circle that worsens the immune-
depression [42].  
Although both IDSA and ISITD guidelines 
recommend secondary prophylaxis with L-AMB in 
patients with a CD4+ T-cell count lower than 200/μl, 
our patient refused it [35] [39]. He is still in follow up 
for the possibility of relapses and recently completed 
his 5
th
 month from the end of the therapy with L-AMB. 
In conclusion, visceral Leishmaniasis is an 
important opportunistic disease in PLWH, with a 
complicated differential diagnosis because of its 
unspecific symptoms and signs. It is even more 
difficult because of the possibility of atypical 
manifestations. 
However, this parasitic disease has a high 
mortality rate, so it is mandatory to think about it in all 
the patients having a low CD4+ T-cell count and an 
inverted CD4/CD8 ratio under HAART. 
Further studies are needed to clear the 
pathogenesis of the infection and to establish the 
duration of the secondary prophylaxis. 
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